Go Pro
→ The dollar reset no one told you about (From Porter & Company) (Ad)tc pixel Free RKDA Stock Alerts

Arcadia Biosciences (RKDA) Competitors

Arcadia Biosciences logo
$0.62 0.00 (-0.74%)
As of 04:00 PM Eastern
Compare

RKDA vs. CEAD, IVP, EDBL, ORIS, and YTEN

Should you buy Arcadia Biosciences stock or one of its competitors? MarketBeat compares Arcadia Biosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Arcadia Biosciences include CEA Industries (CEAD), Inspire Veterinary Partners (IVP), Edible Garden (EDBL), Oriental Rise (ORIS), and Yield10 Bioscience (YTEN). These companies are all part of the "agriculture" industry.

How does Arcadia Biosciences compare to CEA Industries?

Arcadia Biosciences (NASDAQ:RKDA) and CEA Industries (NASDAQ:CEAD) are both small-cap agriculture companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, risk, institutional ownership and valuation.

CEA Industries has a net margin of -118.08% compared to Arcadia Biosciences' net margin of -195.94%. CEA Industries' return on equity of -27.79% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-195.94% -113.73% -68.47%
CEA Industries -118.08%-27.79%-24.75%

In the previous week, Arcadia Biosciences had 2 more articles in the media than CEA Industries. MarketBeat recorded 2 mentions for Arcadia Biosciences and 0 mentions for CEA Industries. Arcadia Biosciences' average media sentiment score of 1.43 beat CEA Industries' score of 0.00 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Arcadia Biosciences Positive
CEA Industries Neutral

17.7% of Arcadia Biosciences shares are held by institutional investors. Comparatively, 21.6% of CEA Industries shares are held by institutional investors. 8.2% of Arcadia Biosciences shares are held by insiders. Comparatively, 4.8% of CEA Industries shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Arcadia Biosciences has higher revenue and earnings than CEA Industries. CEA Industries is trading at a lower price-to-earnings ratio than Arcadia Biosciences, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.86M0.28-$2.34M-$5.73N/A
CEA Industries$3.28M0.69-$2.91M-$4.23N/A

Arcadia Biosciences has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, CEA Industries has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
CEA Industries
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Arcadia Biosciences beats CEA Industries on 7 of the 13 factors compared between the two stocks.

How does Arcadia Biosciences compare to Inspire Veterinary Partners?

Inspire Veterinary Partners (NASDAQ:IVP) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap agriculture companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, risk, analyst recommendations, profitability, media sentiment, dividends, earnings and valuation.

Arcadia Biosciences has lower revenue, but higher earnings than Inspire Veterinary Partners. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Inspire Veterinary Partners, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inspire Veterinary Partners$15.56M0.09-$14.26M-$2.20N/A
Arcadia Biosciences$4.86M0.28-$2.34M-$5.73N/A

In the previous week, Arcadia Biosciences had 2 more articles in the media than Inspire Veterinary Partners. MarketBeat recorded 2 mentions for Arcadia Biosciences and 0 mentions for Inspire Veterinary Partners. Arcadia Biosciences' average media sentiment score of 1.43 beat Inspire Veterinary Partners' score of 0.00 indicating that Arcadia Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Inspire Veterinary Partners Neutral
Arcadia Biosciences Positive

Inspire Veterinary Partners has a beta of -0.49, meaning that its share price is 149% less volatile than the broader market. Comparatively, Arcadia Biosciences has a beta of 0.54, meaning that its share price is 46% less volatile than the broader market.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Inspire Veterinary Partners
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

4.8% of Inspire Veterinary Partners shares are owned by institutional investors. Comparatively, 17.7% of Arcadia Biosciences shares are owned by institutional investors. 6.4% of Inspire Veterinary Partners shares are owned by insiders. Comparatively, 8.2% of Arcadia Biosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Inspire Veterinary Partners has a net margin of -76.75% compared to Arcadia Biosciences' net margin of -195.94%. Arcadia Biosciences' return on equity of -113.73% beat Inspire Veterinary Partners' return on equity.

Company Net Margins Return on Equity Return on Assets
Inspire Veterinary Partners-76.75% -520.34% -55.79%
Arcadia Biosciences -195.94%-113.73%-68.47%

Summary

Arcadia Biosciences beats Inspire Veterinary Partners on 8 of the 13 factors compared between the two stocks.

How does Arcadia Biosciences compare to Edible Garden?

Arcadia Biosciences (NASDAQ:RKDA) and Edible Garden (NASDAQ:EDBL) are both small-cap agriculture companies, but which is the better stock? We will compare the two companies based on the strength of their media sentiment, earnings, risk, valuation, profitability, institutional ownership, dividends and analyst recommendations.

Edible Garden has a net margin of -131.59% compared to Arcadia Biosciences' net margin of -195.94%. Edible Garden's return on equity of 0.00% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-195.94% -113.73% -68.47%
Edible Garden -131.59%N/A -88.36%

17.7% of Arcadia Biosciences shares are owned by institutional investors. Comparatively, 13.0% of Edible Garden shares are owned by institutional investors. 8.2% of Arcadia Biosciences shares are owned by insiders. Comparatively, 0.8% of Edible Garden shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Arcadia Biosciences has higher earnings, but lower revenue than Edible Garden. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Edible Garden, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.86M0.28-$2.34M-$5.73N/A
Edible Garden$12.81M1.49-$17.33M-$109.66N/A

In the previous week, Edible Garden had 14 more articles in the media than Arcadia Biosciences. MarketBeat recorded 16 mentions for Edible Garden and 2 mentions for Arcadia Biosciences. Arcadia Biosciences' average media sentiment score of 1.43 beat Edible Garden's score of 0.71 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Arcadia Biosciences Positive
Edible Garden Positive

Edible Garden has a consensus target price of $45.00, suggesting a potential upside of 1,193.10%. Given Edible Garden's stronger consensus rating and higher possible upside, analysts plainly believe Edible Garden is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Edible Garden
1 Sell rating(s)
0 Hold rating(s)
1 Buy rating(s)
0 Strong Buy rating(s)
2.00

Arcadia Biosciences has a beta of 0.54, suggesting that its share price is 46% less volatile than the broader market. Comparatively, Edible Garden has a beta of 1.7, suggesting that its share price is 70% more volatile than the broader market.

Summary

Edible Garden beats Arcadia Biosciences on 10 of the 16 factors compared between the two stocks.

How does Arcadia Biosciences compare to Oriental Rise?

Arcadia Biosciences (NASDAQ:RKDA) and Oriental Rise (NASDAQ:ORIS) are both small-cap agriculture companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, risk, dividends, earnings, valuation, media sentiment, profitability and analyst recommendations.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00
Oriental Rise
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Arcadia Biosciences has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market. Comparatively, Oriental Rise has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market.

17.7% of Arcadia Biosciences shares are held by institutional investors. 8.2% of Arcadia Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Oriental Rise has higher revenue and earnings than Arcadia Biosciences.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Arcadia Biosciences$4.86M0.28-$2.34M-$5.73N/A
Oriental Rise$12.22M0.04$680KN/AN/A

Oriental Rise has a net margin of 0.00% compared to Arcadia Biosciences' net margin of -195.94%. Oriental Rise's return on equity of 0.00% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Arcadia Biosciences-195.94% -113.73% -68.47%
Oriental Rise N/A N/A N/A

In the previous week, Arcadia Biosciences had 2 more articles in the media than Oriental Rise. MarketBeat recorded 2 mentions for Arcadia Biosciences and 0 mentions for Oriental Rise. Arcadia Biosciences' average media sentiment score of 1.43 beat Oriental Rise's score of 0.00 indicating that Arcadia Biosciences is being referred to more favorably in the media.

Company Overall Sentiment
Arcadia Biosciences Positive
Oriental Rise Neutral

Summary

Oriental Rise beats Arcadia Biosciences on 6 of the 11 factors compared between the two stocks.

How does Arcadia Biosciences compare to Yield10 Bioscience?

Yield10 Bioscience (NASDAQ:YTEN) and Arcadia Biosciences (NASDAQ:RKDA) are both small-cap agriculture companies, but which is the superior stock? We will compare the two companies based on the strength of their analyst recommendations, risk, valuation, dividends, media sentiment, profitability, earnings and institutional ownership.

4.9% of Yield10 Bioscience shares are held by institutional investors. Comparatively, 17.7% of Arcadia Biosciences shares are held by institutional investors. 6.1% of Yield10 Bioscience shares are held by insiders. Comparatively, 8.2% of Arcadia Biosciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Given Yield10 Bioscience's higher possible upside, research analysts clearly believe Yield10 Bioscience is more favorable than Arcadia Biosciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Yield10 Bioscience
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00
Arcadia Biosciences
1 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
1.00

Arcadia Biosciences has higher revenue and earnings than Yield10 Bioscience. Arcadia Biosciences is trading at a lower price-to-earnings ratio than Yield10 Bioscience, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Yield10 Bioscience$60K0.00-$14.45M-$26.12N/A
Arcadia Biosciences$4.86M0.28-$2.34M-$5.73N/A

In the previous week, Arcadia Biosciences had 2 more articles in the media than Yield10 Bioscience. MarketBeat recorded 2 mentions for Arcadia Biosciences and 0 mentions for Yield10 Bioscience. Arcadia Biosciences' average media sentiment score of 1.43 beat Yield10 Bioscience's score of 0.00 indicating that Arcadia Biosciences is being referred to more favorably in the news media.

Company Overall Sentiment
Yield10 Bioscience Neutral
Arcadia Biosciences Positive

Yield10 Bioscience has a net margin of 0.00% compared to Arcadia Biosciences' net margin of -195.94%. Yield10 Bioscience's return on equity of 0.00% beat Arcadia Biosciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Yield10 BioscienceN/A N/A -296.08%
Arcadia Biosciences -195.94%-113.73%-68.47%

Yield10 Bioscience has a beta of 1.48, indicating that its stock price is 48% more volatile than the broader market. Comparatively, Arcadia Biosciences has a beta of 0.54, indicating that its stock price is 46% less volatile than the broader market.

Summary

Arcadia Biosciences beats Yield10 Bioscience on 9 of the 14 factors compared between the two stocks.

Get Arcadia Biosciences News Delivered to You Automatically

Sign up to receive the latest news and ratings for RKDA and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding RKDA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

RKDA vs. The Competition

Export
MetricArcadia BiosciencesMED IndustryMedical SectorNASDAQ Exchange
Market Cap$1.35M$3.62B$6.74B$12.55B
Dividend YieldN/A2.20%2.68%8.00%
P/E Ratio-0.1121.1827.0124.38
Price / Sales0.28309.80584.33117.24
Price / Cash0.5361.9829.2249.36
Price / Book0.268.5710.816.34
Net Income-$2.34M$23.83M$3.58B$330.89M
7 Day Performance-11.86%-3.39%-2.19%-1.06%
1 Month Performance-39.81%6.42%3.16%-0.47%
1 Year Performance-86.95%48.80%26.36%19.88%

Arcadia Biosciences Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
RKDA
Arcadia Biosciences
1.2799 of 5 stars		$0.62
-0.7%		N/A-86.9%$1.35M$4.86MN/A60
CEAD
CEA Industries
N/A$2.71
-1.8%		N/A-69.2%$2.17M$3.28MN/A30
IVP
Inspire Veterinary Partners
N/A$0.03
flat		N/AN/A$1.41M$15.56MN/A156
EDBL
Edible Garden
3.7847 of 5 stars		$0.13
+42.5%		$1.00
+700.0%		-99.6%$684K$12.81MN/A50
ORIS
Oriental Rise
N/A$1.83
flat		N/AN/A$503K$12.22MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:RKDA) was last updated on 7/14/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
DOJ Admits It In Court—Your Cash Can Be Seized Without Warning
The Department of Justice recently argued in court that cash may not be legally your property - raising concer...
Priority Gold | Sponsoredtc pixel
The window is closing
We printed 1,000 copies of this report and 688 are gone—when the last one goes out, we're pulling it offline b...
American Alternative | Sponsoredtc pixel
Urgent: Invest In ‘Elon’s iPhone’ Before July 22nd
Early Apple investors saw peak gains as high as 7,537% after the iPhone launched. Now, multiple insider source...
StocksToTrade | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
PH: Do THESE 4 things to your bank account now …
In a few short months, the US government could gain unprecedented powers over personal bank accounts - includi...
Weiss Ratings | Sponsoredtc pixel
When I found Rolls-Royce under $2, most people thought I was crazy
In 2022, Karim Rahemtulla recommended Rolls-Royce when it traded under $2. The stock climbed more than 1,100% ...
Monument Traders Alliance | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel